Ionis Pharmaceuticals
Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
IONS Key Statistics
Stock Snapshot
As of today, Ionis Pharmaceuticals(IONS) shares are valued at $28.90. The company's market cap stands at 4.84B, with a P/E ratio of -8.73.
On 2026-11-15, Ionis Pharmaceuticals(IONS) stock moved within a range of $27.25 to $29.35. With shares now at $28.90, the stock is trading +6.1% above its intraday low and -1.5% below the session's peak.
Trading activity shows a volume of 5.95M, compared to an average daily volume of 6.55M.
The stock's 52-week range extends from a low of $27.25 to a high of $86.74.
The stock's 52-week range extends from a low of $27.25 to a high of $86.74.
IONS News
Ionis Pharmaceuticals Inc. ((IONS)) has held its Q3 earnings call. Read on for the main highlights of the call. Ionis Pharmaceuticals’ earnings call carried a...
Ionis Pharmaceuticals reported Q3 2026 revenue of US$242.72 million and a net loss of US$109.97 million, and reaffirmed full year revenue guidance of US$875 mil...
Ionis Pharmaceuticals (IONS) announced new long-term data for DAWNZERA, the first and only RNA-targeted medicine for hereditary angioedema, to be presented at t...
Analyst ratings
88%
of 26 ratingsMore IONS News
Ionis Pharmaceuticals (IONS) reset expectations around its triglyceride drug TRYNGOLZA after a slower than hoped commercial ramp, trimming 2026 sales guidance w...
Ionis Pharmaceuticals (NasdaqGS:IONS) cut its full-year TRYNGOLZA sales forecast by roughly 50% after a slower-than-expected launch. Management cited challenge...
On its third-quarter 2026 earnings call, held on Nov. 9, 2026, Ionis (IONS -21.36%) lowered its full-year TRYNGOLZA revenue guidance to approximately $50 millio...
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance. • Ionis...
Technology Ionis Pharma Is Poised To Slam Into A 19-Month Low. Here's Why. Licensing Sales of Ionis Pharmaceuticals' (IONS) triglycerides-lowering drug, Tryngol...
Ionis Pharmaceuticals (IONS Quick QuoteIONS - Free Report) reported $243 million in revenue for the quarter ended September 2026, representing a year-over...
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The result...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.